Remember...

curncman
Posts: 543
Joined: Sat Mar 19, 2022 10:10 am

Re: Remember...STEM CELL Therapy ANTI-AGING Benefits - Dr. Joy Kong

Post by curncman »

STEM CELL Therapy ANTI-AGING Benefits - Dr. Joy Kong



I am well wisher of everyone! GOD will pardon all your sins but not your Central Nervous System! Think Positive!
curncman
Posts: 543
Joined: Sat Mar 19, 2022 10:10 am

Re: Remember...ON Helix 22 - Bio Innovation in Development - Manufacturing Cell and Gene Therapeutics

Post by curncman »

ON Helix 22 - Bio Innovation in Development - Manufacturing Cell and Gene Therapeutics

I am well wisher of everyone! GOD will pardon all your sins but not your Central Nervous System! Think Positive!
curncman
Posts: 543
Joined: Sat Mar 19, 2022 10:10 am

Re: Remember...Panel discussion: developing successful advanced therapy partnerships

Post by curncman »

Panel discussion: developing successful advanced therapy partnerships

I am well wisher of everyone! GOD will pardon all your sins but not your Central Nervous System! Think Positive!
curncman
Posts: 543
Joined: Sat Mar 19, 2022 10:10 am

Re: Remember... George Church, PhD: Rewriting Genomes to Eradicate Disease and Aging

Post by curncman »

George Church, PhD: Rewriting Genomes to Eradicate Disease and Aging


I am well wisher of everyone! GOD will pardon all your sins but not your Central Nervous System! Think Positive!
curncman
Posts: 543
Joined: Sat Mar 19, 2022 10:10 am

Re: Remember... Is Fauci’s prediction of an annual COVID vaccine an attempt to ‘gaslight

Post by curncman »

Is Fauci’s prediction of an annual COVID vaccine an attempt to ‘gaslight’ people that it’s just like the flu?
I am well wisher of everyone! GOD will pardon all your sins but not your Central Nervous System! Think Positive!
curncman
Posts: 543
Joined: Sat Mar 19, 2022 10:10 am

Re: Remember...Amgen says Lumakras cuts risk of lung cancer progression by 34%

Post by curncman »

Amgen says Lumakras cuts risk of lung cancer progression by 34%

Deena Beasley
Sun, September 11, 2022 at 3:05 PM
By Deena Beasley

Sept 11 (Reuters) - Amgen Inc's Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial, the company said on Sunday.

There was no significant difference in overall survival between the two treatments in the confirmatory study required by U.S. regulators as a condition of accelerated approval for Lumakras. But Amgen said the trial was not designed to detect a survival difference.

The company is also testing whether the drug could be effective against lung cancer earlier in the disease, and said last month a small study of Lumakras combined with immunotherapy found high rates of liver toxicity and that further study was needed.

More detailed results from the 345-patient study, including median progression-free survival - the length of time until the cancer begins to worsen - will be presented on Monday at the annual meeting of the European Society for Medical Oncology (ESMO) in Paris.

Wall Street analysts, such as Michael Yee at Jefferies, have said investors expect a modest benefit of around two months for the Amgen drug over chemotherapy.

Amgen said 33% of Lumakras trial patients experienced serious side effects such as diarrhea and elevated liver enzymes, compared with 40% of chemotherapy patients.

The medication is designed to target a mutated form of a gene known as KRAS that occurs in about 13% of non-small cell lung cancers, the most common form of the disease, and less frequently in some other solid tumors.

"We are offering the choice of a pill ... versus chemotherapy that means going to the hospital," Amgen oncology head Jean-Charles Soria told Reuters.

Lumakras was approved by the U.S. Food and Drug Administration last year under an accelerated pathway for advanced lung cancer patients with KRAS mutations whose disease has worsened after treatment with chemotherapy or other medicines.

The agency also asked Amgen to study a lower dose of Lumakras, known chemically as sotorasib. The company said those results are expected in the fourth quarter of this year.

The FDA is slated to make an approval decision on a potential rival KRAS-targeting drug, Mirati Therapeutics Inc's adagrasib, by mid-December.

Mirati in May said adagrasib shrank tumors in 44% of advanced lung cancer patients in clinical trials, but also caused serious side effects in 43% of them.

At the ESMO meeting this week, Amgen is also presenting early data from a trial of Lumakras in combination with other cancer drugs for patients with colorectal cancer.

(Reporting By Deena Beasley Editing by Bill Berkrot)
I am well wisher of everyone! GOD will pardon all your sins but not your Central Nervous System! Think Positive!
curncman
Posts: 543
Joined: Sat Mar 19, 2022 10:10 am

ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive

Post by curncman »

ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ

https://finance.yahoo.com/news/immunity ... 00637.html
I am well wisher of everyone! GOD will pardon all your sins but not your Central Nervous System! Think Positive!
curncman
Posts: 543
Joined: Sat Mar 19, 2022 10:10 am

Re: Remember...Scientists were worried about a particular variant this fall. They didn't expect its offspring

Post by curncman »

Scientists were worried about a particular variant this fall. They didn't expect its offspring

https://www.yahoo.com/finance/news/scie ... 04879.html

Omicron spawn BA.2.75, dubbed “Centaurus,” seemed like the COVID variant to watch this summer—one with the potential to wreak unprecedented havoc later in the year.

The World Health Organization announced in July it was tracking the concerning new variant, which had been identified in 10 countries, including the U.S., and was gaining ground against other transmissible strains of the virus like BA.5 in India.

But Centaurus is no longer a worry, Dr. Raj Rajnarayanan, assistant dean of research and associate professor at the New York Institute of Technology campus in Jonesboro, Ark., told Fortune.

Instead, one of its children, BA.2.75.2, has outcompeted it, eliminating it as a threat—but replacing it with a more formidable one.

It’s one to watch this fall, he says—for more reasons than one.

‘Extensive escape’
Among BA.2.75.2’s concerning traits: Its spike protein binds to human cells tightly—better than any other variant so far, Rajnarayanan says. By doing so, it makes it more difficult for antibodies to successfully attack.

It’s picking up mutations that make it more similar to BA.5 and the deadly Delta variant of late 2021. And it’s just “a couple of mutations away from picking up increased transmission speed,” Rajnarayanan said.

To make matters worse, the new variant shows “extensive escape” ability, according to a new preprint paper released this week by researchers at the Imperial College in London and the Karolinska Institute in Sweden. The paper has not yet been peer reviewed but has been widely cited by experts.

The authors called the Centaurus spawn “the most neutralization-resistant variant evaluated to date,” and said it may effectively evade antibody immunity, built by vaccination and prior infection.

The variant could even escape immunity provided by the last monoclonal antibody treatment effective in currently circulating variants: Bebtelovimab.

“These are our last monoclonal antibodies,” Rajnarayanan said. “For the immunocompromised right now, having monoclonal antibodies is one of the best ways to mitigate infections.”

“If you take the tool away, it’s going to be a problem.”

A coming wave of multiple variants
Rajnarayanan and others, like the Institute for Health Metrics and Evaluation at the University of Washington, foresee a fall COVID wave in the U.S. that begins to rise in late October, and peaks in late December or January.

Rajnarayanan thinks it could be fueled by multiple variants, with BA.2.75.2 likely included.

He encourages all Americans to get boosted, saying the new Omicron bivalent booster is the best tool society has against the virus.

And he shared a bit of good news: While new variants may be “immune evasive,” they won’t evade all of the body’s immune system.

Such variants dodge antibody immunity, produced by B cells. But those cells only comprise half of the immune system. T cells, which comprise the other half, can’t stop infection but can dramatically reduce the severity of it.

Immune-evading variants currently don’t touch those.

“When someone says 'immune escape,' it doesn’t mean it’s going to escape everything,” he said.
I am well wisher of everyone! GOD will pardon all your sins but not your Central Nervous System! Think Positive!
curncman
Posts: 543
Joined: Sat Mar 19, 2022 10:10 am

Athersys Amends Securities Purchase Agreement in Connection with Recent Registered Direct Offering

Post by curncman »

Athersys Amends Securities Purchase Agreement in Connection with Recent Registered Direct Offering

https://finance.yahoo.com/news/athersys ... 00373.html
I am well wisher of everyone! GOD will pardon all your sins but not your Central Nervous System! Think Positive!
curncman
Posts: 543
Joined: Sat Mar 19, 2022 10:10 am

Re: Remember..Data show just 4.4 million Americans have had the new COVID booster, but experts expect accelerating deman

Post by curncman »

Data show just 4.4 million Americans have had the new COVID booster, but experts expect accelerating demand in the coming weeks

Image
I am well wisher of everyone! GOD will pardon all your sins but not your Central Nervous System! Think Positive!
User avatar
Codycrusher
Posts: 566
Joined: Sat Mar 19, 2022 7:51 am

Re: Remember...

Post by Codycrusher »

Can’t stand mandates, I haven’t had 1 booster shot, I would rather get Covid than get a booster shot any day of the week but I take Quadramune and nanostilbene so I’m sure those would help too.
I am anti Covid booster shot.
Post Reply